15 results for "Muhammad Shaalan Beg"
Showing 1–15 · 1.63 seconds · RSS
-
Journal Article Full text
Impact of Diabetes Mellitus on the Outcome of Pancreatic Cancer
Introduction: Diabetes mellitus (DM) has the potential to impact the pathogenesis, treatment, and outcome of pancreatic cancer. This study evaluates the impact of DM on pancreatic cancer survival. Methods: We conducted a retrospective cohort study from the Veterans Affairs (VA) Central Cancer…
Also available at: DOAJ
-
Journal Article
Characteristics and impact of the most-cited palliative oncology studies from 1995 to 2016
Abstract Background Palliative care, as a relatively young field within medicine, has increasingly used original research to validate and standardize its practice. In particular, palliative care has been incorporated into oncology to better address end-of-life decisions and care. The goal of this…
-
Journal Article
Twitter Conversations About Pancreatic Cancer by Health Care Providers and the General Public: Thematic Analysis
Background There is a growing interest in the pattern of consumption of health-related information on social media platforms. ObjectiveWe evaluated the content of discussions around pancreatic cancer on Twitter to identify subtopics of greatest interest to health care providers and the general…
-
Journal Article
Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers
Abstract Acquired resistance to systemic treatments is inevitable in most cancers, but the genetic basis for this in many cancer types has remained elusive due to constraints in obtaining tissue specimens longitudinally. In the management of gastrointestinal cancers, molecular profiling is…
-
Journal Article
A qualitative study to explore the acceptability and usefulness of personalized biofeedback to motivate physical activity in cancer survivors
Objective Many cancer survivors do not meet recommended levels of exercise, despite the benefits physical activity offers. This study aimed to understand experiences of insufficiently active overweight/obese breast or colorectal cancer survivors, in efforts to (1) examine regular physical activity…
-
Journal Article
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma
Importance: Clinical outcomes after curative treatment of resectable pancreatic ductal adenocarcinoma (PDA) remain suboptimal. To assess the potential of early control of systemic disease with multiagent perioperative chemotherapy, we conducted a prospective trial. Objective: To determine 2-year…
-
Journal Article
Surgical Outcome Results From SWOG S1505
OBJECTIVE: The optimal neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. METHODS: S1505 (NCT02562716) was a randomized phase II study of perioperative chemotherapy with mFOLFIRINOX (Arm 1) or gemcitabine/nab-paclitaxel…
-
Journal Article
Survival of cancer survivors with a new pancreatic cancer diagnosis
Abstract Background Persons newly diagnosed with pancreas cancer and who have survived a previous cancer are often excluded from clinical trials, despite limited evidence about their prognosis. We examined the association between previous cancer and overall survival. Methods This US…
-
Journal Article Full text
Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of KRAS
The molecular heterogeneity of KRAS is well established, with a pool of variants comprising >75% of all known mutations; this pool includes mutations in classic codons 12, 13, and 61, as well as 146 and 117. In addition, there are rare variants that are more frequently encountered clinically due to…
-
Journal Article Full text
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
BACKGROUND: In this first-in-human, Phase 1 study of a microRNA-based cancer therapy, the recommended Phase 2 dose (RP2D) of MRX34, a liposomal mimic of microRNA-34a (miR-34a), was determined and evaluated in patients with advanced solid tumours. METHODS: Adults with various solid tumours…
-
Journal Article Full text
Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved for the treatment of ROS1 fusion–positive non–small-cell lung cancer (NSCLC) have antitumor activity, but resistance develops in tumors, and intracranial activity is suboptimal. Repotrectinib is a next-generation ROS1 TKI…